GlassScriptPhysician profile
Rafael A Cortes
NPI 1770729816
$8,802.96
in general payments reported to CMS, 2019-2025
32 companies · $2,165 in 2025
The $2,165 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $224 · 2021: $510 · 2022: $1,520 · 2023: $2,100 · 2024: $1,834 · 2025: $2,165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,098.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,409.69 | 2019-2025 | Rinvoq, Linzess, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,002.88 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $800.83 | 2019-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $657.25 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Genzyme Corporation | $532.87 | 2022-2025 | |
| Celgene Corporation | $342.97 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $335.20 | 2020-2024 | Dificid, Zerbaxa, Zinplava |
| Regeneron Healthcare Solutions, INC. | $326.57 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $307.84 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $275.69 | 2019-2024 | Sutab, Suflave |
| Lilly USA, LLC | $238.95 | 2024-2025 | Omvoh |
| Pfizer INC. | $223.48 | 2021-2025 | |
| Qol Medical, LLC | $148.65 | 2021-2025 | Sucraid, Sucraid |
| Pharmacosmos Therapeutics INC. | $139.52 | 2022-2025 | Monoferric |
| Ironwood Pharmaceuticals, INC | $131.21 | 2021-2024 | Linzess |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $131.01 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $95.82 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $88.28 | 2025 | Ibsrela |
| Daiichi Sankyo INC. | $83.77 | 2021-2023 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $82.71 | 2024-2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $81.56 | 2021-2025 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $55.11 | 2025 | Voquezna |
| Allergan, INC. | $51.34 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $50.20 | 2023-2025 | Givlaari |
| Evoke Pharma, INC. | $41.63 | 2024 | |
| Enterra Medical, INC. | $38.30 | 2023-2024 | |
| Nestle Healthcare Nutrition INC. | $30.52 | 2021-2022 | |
| Amgen INC. | $27.49 | 2022 | |
| Shionogi INC | $21.09 | 2019 | |
| Pharming Healthcare, INC. | $20.50 | 2021 | |
| Medtronic, INC. | $15.52 | 2021 | |
| Ferring Pharmaceuticals INC. | $14.51 | 2024 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rafael Cortes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.